IN8bio (INAB) to Release Earnings on Thursday

IN8bio (NASDAQ:INAB – Get Free Report) is anticipated to release its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect IN8bio to post earnings of ($0.3437) per share for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

IN8bio (NASDAQ:INAB – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.33. On average, analysts expect IN8bio to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Get IN8bio alerts:

IN8bio Stock Up 0.0%

NASDAQ:INAB opened at $0.96 on Wednesday. The company’s 50 day moving average is $1.38 and its 200-day moving average is $1.60. IN8bio has a 12 month low of $0.94 and a 12 month high of $2.73. The firm has a market cap of $9.46 million, a price-to-earnings ratio of -0.37 and a beta of 0.24.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on INAB shares. HC Wainwright reiterated a “buy” rating on shares of IN8bio in a research note on Thursday, June 4th. Weiss Ratings restated a “sell (e+)” rating on shares of IN8bio in a report on Friday, July 17th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $4.00.

Get Our Latest Analysis on INAB

Institutional Investors Weigh In On IN8bio

Several hedge funds have recently made changes to their positions in the stock. HRT Financial LP bought a new position in IN8bio during the fourth quarter valued at about $34,000. Captrust Financial Advisors bought a new stake in shares of IN8bio in the 4th quarter worth approximately $43,000. Citadel Advisors LLC bought a new stake in shares of IN8bio in the 3rd quarter worth approximately $54,000. Two Sigma Investments LP acquired a new stake in shares of IN8bio during the 3rd quarter worth approximately $107,000. Finally, Franklin Resources Inc. grew its holdings in shares of IN8bio by 381.6% during the 4th quarter. Franklin Resources Inc. now owns 914,531 shares of the company’s stock worth $2,048,000 after purchasing an additional 724,637 shares in the last quarter. Institutional investors own 92.05% of the company’s stock.

IN8bio Company Profile

(Get Free Report)

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation.

Read More

• Five stocks we like better than IN8bio
• System Upgrade: First Internet Bancorp Options Surge
• AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
• The AI Chip Blockade Is Creating a Shadow Market
• Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter

Receive News & Ratings for IN8bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IN8bio and related companies with MarketBeat.com's FREE daily email newsletter.